Advertisement
Screener

ARMATA PHARMACEUTICALS, INC. (ARMP) Assets, Fair Value Disclosure

2.8 / 5 stars · 68/120 Roast Me

ARMATA PHARMACEUTICALS, INC. Assets, Fair Value Disclosure

ARMATA PHARMACEUTICALS, INC. (ARMP) had Assets, Fair Value Disclosure of $4.28 million as of 2019-09-30, per its 10-Q filed 2019-11-12.

Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Net Asset (Liability)

us-gaap:AssetsFairValueDisclosure · last filed 2020-03-19

  • 2019-09-30: Assets, Fair Value Disclosure $4.28M.
  • 2019-06-30: Assets, Fair Value Disclosure $3.17M.
  • 2018-12-31: Assets, Fair Value Disclosure $9.43M.
Period endAssets, Fair Value Disclosure
2019-09-30$4.28M
10-Q · filed 2019-11-12
2019-06-30$3.17M
10-Q · filed 2019-08-14
2018-12-31$9.43M
10-K · filed 2020-03-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22